NATCO received the “Best Speciality Brand-SILVER AWARD” for marketing excellence in India, during 2014-15 fiscal year
"Making specialty medicines accessible to all"
We manufacture and market affordable medicines that comply with global standards and strive to achieve market leadership in domestic and international markets
Our latest blockbuster drug Hepcinat (Sofosbuvir) has revolutionised the treatment of Chronic Hepatitis C virus (HCV) and is made available at an affordable price. We are the first company in India to launch this product.
Our products cover three main markets; international formulations, domestic formulations and APIs. Within these areas we are leaders in generic oncology and are taking steps to expand therapeutic segments with a continued focus on niche products.
Natco Trust was founded in 1995 with the desire to serve under-privileged children and poor people in society. As National Award winners For Excellence in CSR & Sustainability, we strongly believe in giving back to the communities in which we function.
Fiscal 2014-15 was an important year in Natco’s journey in terms of our performance. Revenues grew by 11.20% while EBIDTA grew by 8.73% over the same period.
Share price at 3:43PM IST
Share price at 3:56PM IST
We provide a stimulating and challenging work environment for our employees, who get the opportunity to work with state-of-the-art technologies and deliver affordable and life saving drugs globally.
Whether you're a customer, job seeker, health professional or an investor, you can find the best way to contact us.